Abstract
Acute septic arthritis is on the rise among all patients. Acute septic arthritis must be extensively assessed, identified, and treated to prevent fatal consequences. Antimicrobial therapy administered intravenously has long been considered the gold standard for treating acute osteoarticular infections. According to clinical research, parenteral antibiotics for a few days, followed by oral antibiotics, are safe and effective for treating infections without complications. This article focuses on bringing physicians up-to-date on the most recent findings and discussions about the epidemiology, etiology, diagnosis, and treatment of acute septic arthritis. In recent years, the emergence of antibiotic-resistant, particularly aggressive bacterial species has highlighted the need for more research to enhance treatment approaches and develop innovative diagnosis methods and drugs that might combat better in all patients. This article aims to furnish radiologists, orthopaedic surgeons, and other medical practitioners with contemporary insights on the subject matter and foster collaborative efforts to improve patient outcomes. This review represents the initial comprehensive update encompassing patients across all age groups.
Introduction: The Joint Emergency
Acute Septic Arthritis (ASA) is the "heart attack" of the joints—a rapid, painful infection that can lead to permanent disability or systemic sepsis if not caught within hours. Despite its severity, the medical community has long grappled with a lack of consensus on the most effective diagnostic and treatment pathways. This review synthesizes the latest shifts in the field, highlighting the transition from slow traditional cultures to rapid metagenomic sequencing (mNGS) and the move toward shorter, more aggressive treatment protocols.
Pathogen Etiology and Epidemiology
Staphylococcus aureus remains the most prevalent culprit across all age groups. However, "rare" pathogens vary significantly by age: infants are more susceptible to Group B streptococci, while sexually active adults must be screened for Neisseria gonorrhoeae. Epidemiological data shows incidence rates ranging from 1 to 35 cases per 100,000 individuals, with a staggering 16.3% mortality rate. Risk factors include age (over 80), pre-existing joint disease (rheumatoid arthritis), and diabetes.
Diagnostic Revolution: mNGS vs. Traditional Cultures
Traditional diagnostic methods, such as synovial fluid cultures, are notoriously slow and often return false negatives, particularly if the patient has already started antibiotics. Metagenomic Next-Generation Sequencing (mNGS) offers a high-throughput alternative by identifying pathogen DNA directly from samples.
In head-to-head comparisons, mNGS achieved a sensitivity of 88.5%, significantly outperforming the 54-55% sensitivity of traditional blood and synovial fluid cultures. This is particularly vital for patients who have already started antibiotics, which often "sterilize" traditional cultures while leaving detectable DNA behind.
Evolving Treatment Strategies
Antibiotic Duration
One of the most significant shifts in ASA management is the evidence supporting shorter antibiotic courses. Recent research suggests that for uncomplicated cases, a few days of parenteral (IV) antibiotics followed by oral medication is just as effective—and much safer—than weeks of continuous IV therapy.
For specific cases like hand and wrist ASA, a 2-week course of targeted antibiotics was found to be non-inferior to a 4-week course, potentially reducing hospital stays and antibiotic-related side effects without compromising remission rates.
Surgical Management
The review leans heavily toward arthroscopic irrigation over traditional open-joint surgery (arthrotomy). Arthroscopy offers lower reinfection rates, less pain, and faster recovery of joint range of motion. In a study of 79 patients, arthroscopic treatment required an average of only 1.3 operations to eliminate infection, with significantly better long-term mobility outcomes.
Limitations and Future Directions
While mNGS is highly sensitive, it risks "false positives" by detecting harmless skin flora, requiring high-level clinical expertise for interpretation. Furthermore, the continued emergence of multi-drug-resistant species like MRSA necessitates localized research into regional bacterial trends. The future of ASA management lies in multidisciplinary collaboration between radiologists, orthopedic surgeons, and microbiologists to implement high-tech diagnostic tools earlier in the care cycle.
Summary updated